Hologic is positioning its Genius™ AI-driven clinical intelligence platform to capitalize on the projected $70.92 billion point-of-care diagnostics market by 2032. With the CMS ACCESS Model set to begin in July 2026, the company expects outcome-based reimbursement to accelerate adoption of its software-defined imaging solutions. Hologic’s portable SecurView® workstation integrates MRI-level image reconstruction and advanced lesion detection algorithms, enabling clinicians to perform high-resolution breast and musculoskeletal scans at the bedside. Early field tests in five regional clinics reported a 25% reduction in patient transfer to imaging departments and a 15% improvement in diagnostic turnaround time compared with standard workflows.

To combat a recent decline in routine cervical cancer screening—currently at 76% of eligible U.S. women, down from 83% five years ago—Hologic has unveiled the Ultimate Defense public awareness initiative. The multi-channel campaign features collaborations with 120 primary care networks and digital outreach targeting women aged 21 to 65. Hologic will provide no-cost educational modules to over 2,000 healthcare providers, aiming to increase Pap plus HPV co-testing rates by 10 percentage points within 12 months. The company forecasts that every 1% increase in screening compliance could prevent approximately 1,200 new invasive cervical cancer cases annually.

Hologic will release its fiscal 2026 first quarter results on Thursday, January 29, 2026, after market close. In light of its pending acquisition by Blackstone and TPG, the company will forgo a live conference call and will not issue financial guidance for the period. Investors and analysts are focusing on growth in the Diagnostics segment, which delivered 18% year-over-year revenue growth in Q4 2025, and on backlog levels in Breast Health, which stood at $1.3 billion at the end of the last fiscal year.